Cushing's syndrome (CS) is characterized by the overproduction of cortisol that may result in significant morbidity and mortality if left untreated. CS is very rarely caused by ectopic adrenocorticotropic hormone production from several tumors, although pulmonary neuroendocrine tumors (pNETs) are the most common etiology. It is controversial whether such tumors are more clinically aggressive than other pNETs. We herein report an unusual case of severe ectopic CS caused by a small pulmonary carcinoid in the lung with massive neoplastic dissemination to the liver. We highlight and discuss the unusual clinical onset, with diagnostic and therapeutic criticism, of this rare entity. 
A 65-year-old woman presented with a three-month history of severe proximal muscle weakness, polyuria, severe depression, easy bruising, increasing dyspnea and difficultto-treat hypertension.
A physical examination performed on admission revealed clinical signs of severe Cushing's syndrome (CS). The main anthropometric parameters, physical features, clinical symptoms, biochemical data and serological test results are summarized in detail in Table. In particular, the cortisol and adrenocorticotropic hormone (ACTH) values obtained in the morning and evening indicated an impaired circadian rhythm in the setting of ACTHdependent CS. In addition, a high-dose dexamethasone test (8 mg) showed no suppression of the cortisol or ACTH level, and magnetic resonance imaging of the pituitary did not reveal an adenoma. The initial treatment consisted of nifedipine, ramipril and hydrochlorothiazide, which achieved a partial clinical response. A whole-body computed tomography (CT) scan was performed under suspicion of ectopic ACTH secretion (Fig. 1A, B) . As a result, multiple focal lesions were detected in the liver, and a small (13×12-mm diameter) solid nodule was found in the middle lobe of the right lung. Inspired by other reports (1, 2), we performed a dual-tracer positron emission tomography (PET)/ CT sequential evaluation using both 18 F-flurodeoxyglucose (FDG) and 68Ga-DOTATATE (somatostatin analog). The 18 F-FDG PET/CT scan (Fig. 1C, D ) disclosed an intense uptake of the radiotracer corresponding to the pulmonary nodule and multiple liver lesions (SUVmax: 2.6 and 6.4, respectively). Conversely, the 68Ga-DOTATATE PET/CT scan showed no uptake of the radiotracer at the level of the pulmonary nodule or corresponding liver lesions (Fig. 1E, F) .
A CT-guided biopsy using a Tru-Cut needle was performed to obtain tissue from the liver lesions. Morphological and immunohistopathological analyses showed a primary pulmonary (poorly differentiated) carcinoid tumor (Fig. 2) . Chemotherapy was started (cisplatin/etoposide/ifosfamide); however, the dose was interrupted early due to the development of severe (grade G4) hematological toxicity. 
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The present case involved an unusual clinical onset with diagnostic criticism of such a rare entity. In fact, as remarked by Boddaert (3), detecting bronchopulmonary carcinoids (BCs) associated with CS remains difficult and the diagnosis of often delayed despite diagnostic advancements, as BC causing CS may appear as small pulmonary lesions of 5-30 mm in size.
New diagnostic strategies have been developed to improve the rate of detection of such tumors, both in the preoperative and intraoperative setting (4) . Performing a PET/CT scan using a somatostatin analogue is extremely useful for diagnosing pulmonary neuroendocrine tumors (5), with superior accuracy/sensibility rates, as reported in a meta-analysis (6) .
We adopted a similar strategy using both radiotracers to identify the occult source of ACTH. Consequently, the pul- monary lesion appeared to take up FDG (SUVmax, 2.6), and a high metabolic activity was observed at the level of the liver metastases. Conversely, the 68Ga-DOTATATE PET/CT scan showed no uptake of the radiotracer at the level of either the pulmonary nodule or hepatic lesions. With respect to an explanation of these results, we should consider that the expression of somatostatin receptors (ligands for the 68 Ga-DOTATATE radiotracer) is strictly related to the grade of tumor differentiation (5) . Consequently, only limited activity was found in the pulmonary lesion, and even less in the liver metastases, as the carcinoid tumor was poorly differentiated, resulting in a "loss of capacity" to express somatostatin receptors.
Another very interesting issue concerns the extremely aggressive behavior of this entity. Indeed, the clinical presentation (severe CS) and neoplastic dissemination with massive involvement of the liver represent a very unusual onset for such a small pulmonary lesion. Indeed, other authors (1, 3, 7) have hypothesized regarding the biological behavior of BC associated with CS, with some (3) suggesting that the high aggressiveness of these tumors justifies the use of anatomic resection and radical complete lymph node dissection when technically feasible. However, the same authors (3) also concluded that the prognosis, even in N2 disease, remains favorable. Similar results have been reported by Pass et al. (8) . In a series of 13 cases of BC with CS, approximately 55% of the patients presented with mediastinal lymph node metastasis. Of these patients, 85% were found to be alive, despite the short follow-up period (mean follow-up, 21 months), and 71% were symptom-free, while CS persisted in only two patients.
Comparing this case with other similar cases reported in the literature (7, 8) , what is unusual in our patient is that the tumor presented with a very aggressive behavior. In fact, the mitotic count was very high (Ki-67% proliferation index = 20%) and the degree of neoplastic dissemination at diagnosis was impressive considering the radiological absence of lymph node involvement and small size of the primary pulmonary lesion.
Despite the high mitotic count, chemotherapeutic drugs substantially failed to achieve a radiological or clinical response, and the neoplasm progressed rapidly with a continued poor clinical condition related to CS.
In conclusion, this unusual case highlights two challenging issues: the effects of diagnostic criticism during the work-up examination of ectopic ACTH secretion, which may result in a delay in the diagnosis/treatment of the tumor, and, simultaneously, the need to clinically control CS. Additionally, the oncological presentation and evolution of such tumors, which may be unpredictable and insidious, reflects the necessity of providing an aggressive, multidisciplinary, tailored strategy for care.
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